NCT07383025 Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
| NCT ID | NCT07383025 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bristol-Myers Squibb |
| Condition | Obstructive Hypertrophic Cardiomyopathy (oHCM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-05-21 |
| Primary Completion | 2029-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-05-21 with a primary completion date of 2029-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
Eligibility Criteria
Inclusion Criteria: • All obstructive hypertrophic cardiomyopathy (oHCM) patients who initiate treatment with Mavacamten of the approved indications at medical institutions in Japan during enrollment period will be enrolled in this regulatory post-marketing surveillance (PMS) study Exclusion Criteria: • Participants receiving Mavacamten for an off-label indication will be excluded from this PMS study
Contact & Investigator
Bristol Myers Squibb
STUDY DIRECTOR
Bristol-Myers Squibb
Frequently Asked Questions
Who can join the NCT07383025 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obstructive Hypertrophic Cardiomyopathy (oHCM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07383025 currently recruiting?
Yes, NCT07383025 is actively recruiting participants. Contact the research team at Clinical.Trials@bms.com for enrollment information.
Where is the NCT07383025 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT07383025 clinical trial?
NCT07383025 is sponsored by Bristol-Myers Squibb. The principal investigator is Bristol Myers Squibb at Bristol-Myers Squibb. The trial plans to enroll 200 participants.